Tertiary lymphoid structures in the era of cancer immunotherapy.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
17
5
2019
medline:
5
7
2019
entrez:
17
5
2019
Statut:
ppublish
Résumé
Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis have been identified. TLSs exist under different maturation states in tumours, culminating in germinal centre formation. The mechanisms that underlie the role of TLSs in the adaptive antitumour immune response are being deciphered. The description of the correlation between TLS presence and clinical benefit in patients with cancer, suggesting that TLSs could be a prognostic and predictive factor, has drawn strong interest into investigating the role of TLSs in tumours. A current major challenge is to exploit TLSs to promote lymphocyte infiltration, activation by tumour antigens and differentiation to increase the antitumour immune response. Several approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic scaffolds to induce TLS formation. Strategies aiming to induce TLS neogenesis in immune-low tumours and in immune-high tumours, in this case, in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors, represent promising avenues for cancer treatment.
Identifiants
pubmed: 31092904
doi: 10.1038/s41568-019-0144-6
pii: 10.1038/s41568-019-0144-6
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
307-325Références
Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988).
pubmed: 2841597
doi: 10.1056/NEJM198809013190901
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
doi: 10.1126/science.aaa4971
pubmed: 25838375
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531
doi: 10.1126/science.1129139
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
pubmed: 28741618
doi: 10.1038/nrclinonc.2017.101
Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
pubmed: 22193102
pmcid: 3967235
doi: 10.1038/nature10673
Drayton, D. L., Liao, S., Mounzer, R. H. & Ruddle, N. H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7, 344–353 (2006).
pubmed: 16550197
doi: 10.1038/ni1330
Dieu-Nosjean, M.-C. et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260–275 (2016).
pubmed: 27088920
doi: 10.1111/imr.12405
Lucchesi, D. & Bombardieri, M. The role of viruses in autoreactive B cell activation within tertiary lymphoid structures in autoimmune diseases. J. Leukoc. Biol. 94, 1191–1199 (2013).
pubmed: 23812327
doi: 10.1189/jlb.0413240
Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).
pubmed: 24948366
doi: 10.1038/nri3700
Dieu-Nosjean, M.-C., Goc, J., Giraldo, N. A., Sautès-Fridman, C. & Fridman, W. H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35, 571–580 (2014).
pubmed: 25443495
doi: 10.1016/j.it.2014.09.006
Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6, 205–217 (2006).
pubmed: 16498451
doi: 10.1038/nri1786
Thaunat, O. et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc. Natl Acad. Sci. USA 102, 14723–14728 (2005).
pubmed: 16192350
doi: 10.1073/pnas.0507223102
pmcid: 1253595
Thaunat, O. et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J. Immunol. 185, 717–728 (2010).
pubmed: 20525884
doi: 10.4049/jimmunol.0903589
Moyron-Quiroz, J. E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927–934 (2004).
pubmed: 15311275
doi: 10.1038/nm1091
Moyron-Quiroz, J. E. et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643–654 (2006).
pubmed: 17045819
doi: 10.1016/j.immuni.2006.08.022
Ramos-Casals, M., De Vita, S. & Tzioufas, A. G. Hepatitis C virus, Sjögren’s syndrome and B cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun. Rev. 4, 8–15 (2005).
pubmed: 15652773
doi: 10.1016/j.autrev.2004.04.004
Mazzucchelli, L. et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J. Clin. Invest. 104, R49–R54 (1999).
pubmed: 10562310
pmcid: 481995
doi: 10.1172/JCI7830
Sautès-Fridman, C. et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front. Immunol. 7, 407 (2016).
pubmed: 27752258
pmcid: 5046074
doi: 10.3389/fimmu.2016.00407
Martinet, L. et al. Human solid tumors contain high endothelial venules: association with T
pubmed: 21846823
doi: 10.1158/0008-5472.CAN-11-0431
Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832–844 (2014). This study describes the favourable prognostic impact of follicular B cells and the production of antitumour antibodies by intratumoural B cells.
pubmed: 24484236
doi: 10.1164/rccm.201309-1611OC
Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016). This paper describes the favourable impact of tumour-infiltrating plasma cells on the antitumour immune response.
pubmed: 26763251
doi: 10.1158/1078-0432.CCR-15-2762
Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cells. Cancer Res. 74, 705–715 (2014). This paper demonstrates the impact of mature DCs located in TLSs on the antitumoural activity of CD8
pubmed: 24366885
doi: 10.1158/0008-5472.CAN-13-1342
Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated with T cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147–2158 (2014).
pubmed: 24523438
doi: 10.1158/1078-0432.CCR-13-2590
Finkin, S. et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16, 1235–1244 (2015).
pubmed: 26502405
pmcid: 4653079
doi: 10.1038/ni.3290
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
pubmed: 29567705
doi: 10.1126/science.aar4060
pmcid: 7391259
Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
pubmed: 24714771
pmcid: 4185001
doi: 10.1158/1078-0432.CCR-13-3271
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
pubmed: 26940869
pmcid: 4984254
doi: 10.1126/science.aaf1490
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
pubmed: 30643254
doi: 10.1038/s41588-018-0312-8
pmcid: 6365097
Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853–1860 (2018). This paper shows that TLS presence is associated with pathological response to neoadjuvant anti-PD1.
pubmed: 29982279
doi: 10.1093/annonc/mdy218
pmcid: 6096736
Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8 +T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994–1004 (2018). This study demonstrates that PD1
pubmed: 29892065
pmcid: 6110381
doi: 10.1038/s41591-018-0057-z
Maldonado, L. et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl Med. 6, 221ra13 (2014). This study shows induction of TLSs upon therapeutic vaccination.
pubmed: 24477000
pmcid: 4086631
doi: 10.1126/scitranslmed.3007323
Hill, D. G. et al. Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. Int. J. Cancer 143, 167–178 (2018).
pubmed: 29417587
pmcid: 5969244
doi: 10.1002/ijc.31298
Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43, 579–590 (2015).
pubmed: 26341400
pmcid: 4826619
doi: 10.1016/j.immuni.2015.08.006
Spratt, J. S. & Spjut, H. J. Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 20, 1976–1985 (1967).
pubmed: 6061631
doi: 10.1002/1097-0142(196711)20:11<1976::AID-CNCR2820201125>3.0.CO;2-M
Ladányi, A. et al. Density of DC-LAMP+mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459–1469 (2007).
pubmed: 17279413
doi: 10.1007/s00262-007-0286-3
Dieu-Nosjean, M.-C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008).
pubmed: 18802153
doi: 10.1200/JCO.2007.15.0284
Nielsen, J. S. et al. CD20+tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012).
pubmed: 22553348
doi: 10.1158/1078-0432.CCR-12-0234
Gu-Trantien, C. et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight 2, 91487 (2017).
pubmed: 28570278
doi: 10.1172/jci.insight.91487
Martinet, L. et al. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β–producing dendritic cells in human breast cancer. J. Immunol. 191, 2001–2008 (2013).
pubmed: 23825314
doi: 10.4049/jimmunol.1300872
Streeter, P. R., Rouse, B. T. & Butcher, E. C. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. J. Cell Biol. 107, 1853–1862 (1988).
pubmed: 2460470
doi: 10.1083/jcb.107.5.1853
Girard, J.-P. & Springer, T. A. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 16, 449–457 (1995).
pubmed: 7546210
doi: 10.1016/0167-5699(95)80023-9
de Chaisemartin, L. et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71, 6391–6399 (2011).
pubmed: 21900403
doi: 10.1158/0008-5472.CAN-11-0952
Engelhard, V. H. et al. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J. Immunol. 200, 432–442 (2018).
pubmed: 29311385
doi: 10.4049/jimmunol.1701269
Hennequin, A. et al. Tumor infiltration by Tbet+effector T cells and CD20+B cells is associated with survival in gastric cancer patients. Oncoimmunology 5, e1054598 (2016).
pubmed: 27057426
doi: 10.1080/2162402X.2015.1054598
Gobert, M. et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69, 2000–2009 (2009).
pubmed: 19244125
doi: 10.1158/0008-5472.CAN-08-2360
Ruddle, N. H. High endothelial venules and lymphatic vessels in tertiary lymphoid organs: characteristics, functions, and regulation. Front. Immunol. 7, 491 (2016).
pubmed: 27881983
pmcid: 5101196
doi: 10.3389/fimmu.2016.00491
Montfort, A. et al. A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017).
pubmed: 27354470
doi: 10.1158/1078-0432.CCR-16-0081
García-Hernández, M. L. et al. A unique cellular and molecular microenvironment is present in tertiary lymphoid organs of patients with spontaneous prostate cancer regression. Front. Immunol. 8, 563 (2017).
pubmed: 28567040
pmcid: 5434117
doi: 10.3389/fimmu.2017.00563
Carrega, P. et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun. 6, 8280 (2015).
pubmed: 26395069
doi: 10.1038/ncomms9280
Barone, F. et al. Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front. Immunol. 7, 477 (2016).
pubmed: 27877173
pmcid: 5100680
doi: 10.3389/fimmu.2016.00477
Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011). This paper demonstrates the application of a 12-chemokine gene signature for TLS detection.
pubmed: 21703392
pmcid: 3123872
doi: 10.1016/j.ajpath.2011.03.007
Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).
pubmed: 23097687
pmcid: 3479449
doi: 10.1038/srep00765
Prabhakaran, S. et al. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res. 19, 71 (2017).
pubmed: 28629479
pmcid: 5477261
doi: 10.1186/s13058-017-0864-z
Gu-Trantien, C. et al. CD4+follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013). This study describes the favourable prognostic impact of PD1
pubmed: 23778140
pmcid: 3696556
doi: 10.1172/JCI67428
Becht, E. et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer Res. 22, 4057–4066 (2016).
pubmed: 26994146
doi: 10.1158/1078-0432.CCR-15-2879
Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).
pubmed: 27765066
pmcid: 5073889
doi: 10.1186/s13059-016-1070-5
Cipponi, A. et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72, 3997–4007 (2012).
pubmed: 22850419
doi: 10.1158/0008-5472.CAN-12-1377
Lee, M. et al. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod. Pathol. 32, 70–80 (2018). This study demonstrates that the organs to which melanoma metastases seed also influence TLS densities.
pubmed: 30154578
doi: 10.1038/s41379-018-0113-8
Silin¸a, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308–1320 (2018). This paper shows that TLSs are impaired by corticosteroids.
doi: 10.1158/0008-5472.CAN-17-1987
Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861–868 (2011).
pubmed: 20966025
doi: 10.1136/gut.2010.226092
Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7, e1378844 (2017).
pubmed: 29416939
pmcid: 5798199
doi: 10.1080/2162402X.2017.1378844
Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782–1790 (2015).
pubmed: 25942397
pmcid: 4647237
doi: 10.1038/bjc.2015.145
Castino, G. F. et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology 5, e1085147 (2016).
pubmed: 27141376
doi: 10.1080/2162402X.2015.1085147
Wirsing, A. M. et al. Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma. Mod. Pathol. 31, 910–922 (2018).
pubmed: 29416107
doi: 10.1038/s41379-018-0019-5
Lee, H. J. et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am. J. Clin. Pathol. 144, 278–288 (2015).
pubmed: 26185313
doi: 10.1309/AJCPIXUYDVZ0RZ3G
Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13, 228–241 (2016).
pubmed: 26667975
doi: 10.1038/nrclinonc.2015.215
Truxova, I. et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6, 139 (2018).
pubmed: 30526667
pmcid: 6288908
doi: 10.1186/s40425-018-0446-3
Schlößer, H. A. et al. B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. Oncoimmunology 8, e1512458 (2019).
pubmed: 30546950
doi: 10.1080/2162402X.2018.1512458
Coronella, J. A. et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 169, 1829–1836 (2002).
pubmed: 12165506
doi: 10.4049/jimmunol.169.4.1829
Nzula, S., Going, J. J. & Stott, D. I. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 63, 3275–3280 (2003).
pubmed: 12810659
Petitprez, F. et al. A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy [abstract]. Cancer Res. 78 (Suppl. 13), 4045 (2018).
Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135 (2018).
pubmed: 30049748
doi: 10.1158/1078-0432.CCR-18-1481
Gnjatic, S. et al. Survey of naturally occurring CD4+T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl Acad. Sci. USA 100, 8862–8867 (2003).
pubmed: 12853579
doi: 10.1073/pnas.1133324100
pmcid: 166404
Prilliman, K. R. et al. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J. Immunol. 169, 4094–4097 (2002).
pubmed: 12370335
doi: 10.4049/jimmunol.169.8.4094
Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480–483 (1998).
pubmed: 9624005
doi: 10.1038/31002
Bennett, S. R. et al. Help for cytotoxic-T cell responses is mediated by CD40 signalling. Nature 393, 478–480 (1998).
pubmed: 9624004
doi: 10.1038/30996
Zhu, W. et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4(+) T cell receptor repertoire clonality. Oncoimmunology 4, e1051922 (2015).
pubmed: 26587322
pmcid: 4635865
doi: 10.1080/2162402X.2015.1051922
Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019).
pubmed: 30510250
doi: 10.1038/s41591-018-0266-5
Simoni, Y. et al. Bystander CD8+T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
pubmed: 29769722
doi: 10.1038/s41586-018-0130-2
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174
pmcid: 4856474
doi: 10.1016/j.cell.2014.12.033
Becht, E. et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv. Immunol. 130, 95–190 (2016).
pubmed: 26923001
doi: 10.1016/bs.ai.2015.12.002
Calderaro, J. et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 67, 727–738 (2017).
pubmed: 28532995
doi: 10.1016/j.jhep.2017.05.014
Pikarsky, E. & Heikenwalder, M. Focal and local: ectopic lymphoid structures and aggregates of myeloid and other immune cells in liver. Gastroenterology 151, 780–783 (2016).
pubmed: 27693322
doi: 10.1053/j.gastro.2016.09.029
Sautès-Fridman, C. & Fridman, W. H. TLS in tumors: what lies within. Trends Immunol. 37, 1–2 (2016).
pubmed: 26706045
doi: 10.1016/j.it.2015.12.001
Kuang, D.-M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51, 154–164 (2010).
pubmed: 19902483
doi: 10.1002/hep.23291
Chen, M.-M. et al. Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization. Cancer Discov. 6, 1182–1195 (2016).
pubmed: 27531854
doi: 10.1158/2159-8290.CD-16-0329
Xiao, X. et al. PD-1hi identifies a novel regulatory B cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016).
pubmed: 26928313
doi: 10.1158/2159-8290.CD-15-1408
Calderaro, J. et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J. Hepatol. 70, 58–65 (2018). Together with Finkin et al., this paper shows that the location of TLSs is important for their antitumour function. TLSs located in inflamed tumour-adjacent zones have a pro-tumoural role and can serve as a niche for tumour cell progenitors in HCC, favouring late recurrence. Intratumoural TLSs have a favourable prognostic impact on early recurrence in HCC.
pubmed: 30213589
doi: 10.1016/j.jhep.2018.09.003
Martinet, L. et al. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 1, 829–839 (2012).
pubmed: 23162750
pmcid: 3489738
doi: 10.4161/onci.20492
Koti, M. et al. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. Bladder Cancer 3, 259–267 (2017).
pubmed: 29152550
pmcid: 5676768
doi: 10.3233/BLC-170120
Liu, X. et al. Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers. Oncologist 22, 1316–1324 (2017).
pubmed: 28701569
pmcid: 5679825
doi: 10.1634/theoncologist.2017-0029
Figenschau, S. L., Fismen, S., Fenton, K. A., Fenton, C. & Mortensen, E. S. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15, 101 (2015).
pubmed: 25884667
pmcid: 4357183
doi: 10.1186/s12885-015-1116-1
Buisseret, L. et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology 6, e1257452 (2017).
pubmed: 28197375
doi: 10.1080/2162402X.2016.1257452
Cimino-Mathews, A. et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum. Pathol. 47, 52–63 (2016).
pubmed: 26527522
doi: 10.1016/j.humpath.2015.09.003
Schweiger, T. et al. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin. Exp. Metastasis 33, 727–739 (2016).
pubmed: 27449756
pmcid: 5035322
doi: 10.1007/s10585-016-9813-y
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M. & Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749–752 (2010).
pubmed: 20339029
doi: 10.1126/science.1185837
Colbeck, E. J. et al. Treg depletion licenses T cell–driven HEV neogenesis and promotes tumor destruction. Cancer Immunol. Res. 5, 1005–1015 (2017).
pubmed: 28947544
pmcid: 5668144
doi: 10.1158/2326-6066.CIR-17-0131
Hindley, J. P. et al. T cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Res. 72, 5473–5482 (2012).
pubmed: 22962270
pmcid: 3491872
doi: 10.1158/0008-5472.CAN-12-1912
Neyt, K., GeurtsvanKessel, C. H., Deswarte, K., Hammad, H. & Lambrecht, B. N. Early IL-1 signaling promotes iBALT induction after influenza virus infection. Front. Immunol. 7, 312 (2016).
pubmed: 27579026
pmcid: 4985557
doi: 10.3389/fimmu.2016.00312
Kennedy, C. L. et al. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. J. Pathol. 225, 255–264 (2011).
pubmed: 21710691
doi: 10.1002/path.2933
Barone, F. et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl Acad. Sci. USA 112, 11024–11029 (2015).
pubmed: 26286991
doi: 10.1073/pnas.1503315112
pmcid: 4568258
Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015).
pubmed: 25688160
doi: 10.1158/1078-0432.CCR-14-2926
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366
doi: 10.1158/1078-0432.CCR-16-2848
Giraldo, N. A., Becht, E., Vano, Y., Sautès-Fridman, C. & Fridman, W. H. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch. 467, 127–135 (2015).
pubmed: 26077464
doi: 10.1007/s00428-015-1787-7
Remark, R. et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin. Cancer Res. 19, 4079–4091 (2013). This study shows that the tumour origin dictates the prognostic impact of CD8
pubmed: 23785047
doi: 10.1158/1078-0432.CCR-12-3847
Meshcheryakova, A. et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLOS ONE 9, e99008 (2014).
pubmed: 24905750
pmcid: 4048213
doi: 10.1371/journal.pone.0099008
Finkelman, F. D. et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 303–333 (1990).
pubmed: 1693082
doi: 10.1146/annurev.iy.08.040190.001511
Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
pubmed: 22419253
doi: 10.1038/nrc3245
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
pubmed: 25838373
doi: 10.1126/science.aaa8172
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015).
pubmed: 26678337
doi: 10.1016/j.ccell.2015.10.012
Strom, T. et al. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur. J. Cancer 84, 304–314 (2017).
pubmed: 28863385
pmcid: 5822441
doi: 10.1016/j.ejca.2017.08.001
Sharabi, A. B., Lim, M., DeWeese, T. L. & Drake, C. G. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16, e498–e509 (2015).
pubmed: 26433823
doi: 10.1016/S1470-2045(15)00007-8
Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
pubmed: 23307859
pmcid: 3752683
doi: 10.1158/1078-0432.CCR-12-1630
Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40–50 (2018).
pubmed: 29233559
doi: 10.1016/S1470-2045(17)30904-X
Song, I. H. et al. Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res. Treat. 49, 399–407 (2017).
pubmed: 27488875
doi: 10.4143/crt.2016.215
Stowman, A. M. et al. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 28, 237 (2018).
pubmed: 29538091
doi: 10.1097/CMR.0000000000000439
pmcid: 5912978
Eroglu, Z. et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553, 347–350 (2018).
pubmed: 29320474
pmcid: 5773412
doi: 10.1038/nature25187
Boivin, G. et al. Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy. Front. Oncol. 8, 256 (2018).
pubmed: 30038899
pmcid: 6046619
doi: 10.3389/fonc.2018.00256
Remark, R. et al. Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. Oncoimmunology 5, e1255394 (2016).
pubmed: 28123901
pmcid: 5213838
doi: 10.1080/2162402X.2016.1255394
Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl Med. 9, eaak9679 (2017).
pubmed: 28404866
pmcid: 5554432
doi: 10.1126/scitranslmed.aak9679
Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616–631 (2014).
pubmed: 24942756
pmcid: 4082460
doi: 10.1158/2326-6066.CIR-14-0027
Johansson-Percival, A. et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207–1217 (2017). This paper demonstrates that targeting LIGHT to tumour vessels via a VTP induces formation of intratumoural TLSs and prolongs survival in combination with immune checkpoint inhibitors in mice.
pubmed: 28892469
doi: 10.1038/ni.3836
Chen, L. et al. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther. 20, 469–477 (2013).
pubmed: 23846252
pmcid: 3775601
doi: 10.1038/cgt.2013.42
Weinstein, A. M. et al. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. OncoImmunology 6, e1322238 (2017).
pubmed: 28680760
pmcid: 5486180
doi: 10.1080/2162402X.2017.1322238
Weinstein, A. M. et al. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunol. Immunother. 68, 109–120 (2018).
pubmed: 30315348
doi: 10.1007/s00262-018-2259-0
pmcid: 7185158
Yang, S.-C. et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 66, 3205–3213 (2006).
pubmed: 16540672
doi: 10.1158/0008-5472.CAN-05-3619
Lee, J. M. et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+T cell infiltration. Clin. Cancer Res. 23, 4556–4568 (2017).
pubmed: 28468947
pmcid: 5599263
doi: 10.1158/1078-0432.CCR-16-2821
Zhu, G. et al. Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front. Immunol. 9, 1609 (2018).
pubmed: 30061886
pmcid: 6054958
doi: 10.3389/fimmu.2018.01609
Yagawa, Y. et al. Systematic screening of chemokines to identify candidates to model and create ectopic lymph node structures for cancer immunotherapy. Sci. Rep. 7, 15996 (2017).
pubmed: 29167448
pmcid: 5700067
doi: 10.1038/s41598-017-15924-2
Zhu, G. et al. Tumor-associated tertiary lymphoid structures: gene-expression profiling and their bioengineering. Front. Immunol. 8, 767 (2017).
pubmed: 28713385
pmcid: 5491937
doi: 10.3389/fimmu.2017.00767
Weiden, J., Tel, J. & Figdor, C. G. Synthetic immune niches for cancer immunotherapy. Nat. Rev. Immunol. 18, 212–219 (2017).
pubmed: 28853444
doi: 10.1038/nri.2017.89
Jones, G. W., Hill, D. G. & Jones, S. A. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Front. Immunol. 7, 401 (2016).
pubmed: 27752256
pmcid: 5046062
doi: 10.3389/fimmu.2016.00401
Meier, D. et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 26, 643–654 (2007).
pubmed: 17521585
doi: 10.1016/j.immuni.2007.04.009
Deteix, C. et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J. Immunol. 184, 5344–5351 (2010).
pubmed: 20357253
doi: 10.4049/jimmunol.0902999
Peters, A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986–996 (2011).
pubmed: 22177922
pmcid: 3422678
doi: 10.1016/j.immuni.2011.10.015
Lochner, M. et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J. Exp. Med. 208, 125–134 (2011).
pubmed: 21173107
pmcid: 3023125
doi: 10.1084/jem.20100052
Guedj, K. et al. M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc. Res. 101, 434–443 (2014).
pubmed: 24272771
doi: 10.1093/cvr/cvt263
Colbeck, E. J., Ager, A., Gallimore, A. & Jones, G. W. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front. Immunol. 8, 1830 (2017).
pubmed: 29312327
pmcid: 5742143
doi: 10.3389/fimmu.2017.01830
Furtado, G. C. et al. Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc. Natl Acad. Sci. USA 104, 5026–5031 (2007).
pubmed: 17360402
doi: 10.1073/pnas.0606697104
pmcid: 1829258
Luther, S. A. et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169, 424–433 (2002).
pubmed: 12077273
doi: 10.4049/jimmunol.169.1.424
Fleige, H. et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J. Exp. Med. 211, 643–651 (2014).
pubmed: 24663215
pmcid: 3978277
doi: 10.1084/jem.20131737
Denton, A. E. et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J. Exp. Med. 216, 621–637 (2019).
pubmed: 30723095
doi: 10.1084/jem.20181216
pmcid: 6400543